MedTech Spectrum

Article Name China

WORK Medical Grants East China Distribution Rights for AI-Automated Blood Cell Morphology Analyzer

The collaboration is expected to accelerate market access and drive large-scale commercialisation of the new product

30th December, 2025

Everest Medicines Announces Commercialisation Service Agreement and License Agreement with Hasten

The two agreements are expected to create significant financial and strategic synergies

15th December, 2025

China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology

The Jianxing centre in East China will be the first CGI centre to install X-ray technology

11th December, 2025

Singleron's Matrix NEO Receives Class II Medical Device Approval for Automated Single Cell Analysis

Matrix NEO is the world's first automated single-cell analysis platform to achieve medical device clearance, marking a milestone in bringing single-cell sequencing from research laboratories into clinical practice

17th November, 2025

CoolMPS Brings a New Dimension to Sequencing

The collaboration enables MGI to leverage Swiss Rockets’ strong R&D capabilities and established presence in Europe and the U.S. to commercialise CoolMPS™

10th November, 2025

China Launches Magnetic Resonance Platform for Brain-Computer Interface Research

It enables non-invasive, high-resolution in vivo analysis of the entire brain, significantly improving precision in both space and time

07th November, 2025

Sandstone Easydrip Plus with Hextra Tech Hexagonal Broad Hub Delivers Steadier, More Comfortable Insulin Injections

Pen-needle stability and comfort directly influence user confidence and adherence

03rd November, 2025

Fangzhou’s XingJie LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations

The successful filing of the XJ LLM represents a milestone in Fangzhou’s AI-enabled chronic disease management ecosystem

03rd November, 2025

Fangzhou and Fosun Pharma Forge Strategic Alliance to Deliver AI-Powered Psoriasis Management

Through this collaboration, Fangzhou’s AI Health Manager will offer personalised care guidance and monitoring

31st October, 2025

HighTide’s HTD1801 Shows Long-Term Benefits for Type 2 Diabetes in Phase III Studies

The 52-week data from these two Phase III clinical trials demonstrate the durability of response and highlight the comprehensive long-term clinical benefits of HTD1801 in patients with T2DM

31st October, 2025

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101

This collaboration marks Everest’s strategic expansion into ophthalmology, a high-potential “blue-ocean” therapeutic area

31st October, 2025

MGI Tech announces licensing agreement with Swiss Rockets AG

The strategic partnership is set to fully unlock the patent value and productisation capabilities of CoolMPS, complementing MGI's tried-and-true StandardMPS technology

29th October, 2025

Fangzhou Unveils AI + Weight Management Innovation at China’s Weight Management Symposium in Beijing

China has designated weight management as a national health priority, integrating it into the Healthy China 2030 strategy through a series of government-led initiatives

24th October, 2025

Everest Medicines Enrols First Patient in Global Trial of mRNA Cancer Vaccine EVM14

EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, was developed based on Everest Medicines' proprietary mRNA platform

15th October, 2025

Smartee launches Sleep Aligner Combining Anti-Snoring Therapy with Teeth Alignment

The Smartee Sleep Aligners Series addresses this challenge through digitally customised clear aligners with a dual-splint locking system that advances the mandible while distributing occlusal forces to stabilise the jaw

13th October, 2025

PHASE Scientific Launches World’s Largest Clinical Study on Urine-Based Cervical Cancer Screening in China

The 17,000-woman study, led by Peking University Shenzhen Hospital, sets three world records and integrates PHASiFY™ DNA concentration technology with AI-powered diagnostics to advance scalable, non-invasive screening in line with WHO’s 2030 elimination goals.

23rd September, 2025

PHASE Scientific Launches Urine-Based Cervical Cancer (HPV) Screening Clinical Study

The study applies PHASE Scientific’s proprietary PHASiFY urine-based DNA concentration technology

22nd September, 2025

China’s Healthcare Investment Climate: Rebalancing Global and Local Innovation

Yang Huang, Head of China Healthcare Research at J.P. Morgan, unpacks how favourable policies, demographic shifts, and global collaborations are shaping the future of biopharma and medtech investment in China.

19th September, 2025